Halozyme Confirms Proposal to Combine with Evotec for €11.00 …
1 day ago · News provided by Halozyme Therapeutics, Inc. Nov 14, 2024, 16:15 ET. Share this article. Share to X. Share this article. Share to X. Combination Would Create a Global Innovative Services Company ...
Halozyme’s Strategic Acquisition of Evotec: A Buy Rating for …
14 hours ago · Halozyme (HALO) Company Description: Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates.
Halozyme Confirms Proposal to Combine with Evotec for €11.00 …
1 day ago · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO ...
Halozyme Confirms Proposal to Combine with Evotec for €11.00 …
1 day ago · SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and ...
Halozyme offers $2B for Evotec to expand beyond tech used by J&J
12 hours ago · News of the offer arrived days after Bloomberg reported that the private equity group Triton Partners, which has built an almost 10% stake in Evotec, was weighing a move to acquire the drug ...
Germany’s Evotec Gets Takeover Interest From Halozyme
1 day ago · Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German drug developer at €2 billion ($2.1 billion).
News | Halozyme
Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and …
Halozyme Announces FDA Approval of Roche's Tecentriq …
SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for...
Halozyme Announces Expansion of Global Collaboration and …
Oct 3, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to...
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News …
1 day ago · Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of Halozyme were down 5.1% in aftermarket trade. Earlier this week private equity firm Triton was also reportedly exploring a potential buyout of Evotec, after it confirmed …